BioCentury
ARTICLE | Clinical News

BIT225: Preliminary Phase IIa data

October 17, 2011 7:00 AM UTC

Preliminary data from a double-blind, Thai Phase IIa trial in 24 treatment-naïve patients with HCV genotype 1 infection showed that 200 and 400 mg oral BIT225 for 28 days plus standard of care (SOC; p...